Literature DB >> 35983428

Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity.

Zhaoqiang Dong1, Yuzhen Wang2, Jing Guo3, Chuan Tian4, Wengu Pan4, Hongwei Wang4, Jieke Yan4.   

Abstract

Objective: To evaluate the prostate cancer therapy efficiency of the synergistic combination docetaxel (DTX) and formononetin (FMN) in one nano-sized drug delivery system. Hyaluronic acid (HA) and epidermal growth factor receptor-targeted peptide (GE11) dual ligands were applied to modify the nano-systems.
Methods: In this study, GE11-modified nanoparticles (GE-NPs) were applied for the loading of DTX, and HA-decorated NPs (HA-NPs) were used to encapsulate FMN. HA and GE11 dual ligand-modified binary nanoparticles (HAGE-DTX/FMN-NPs) were constructed by the self-assembling of GE-NPs and HA-NPs. The anti-PCa ability of the system was evaluated in vitro on PC-3 human prostate carcinoma cells (PC3 cells) and in vivo on PC3 tumor-bearing mice in comparison with single NPs and free drugs formulations.
Results: HA/GE-DTX/FMN-NPs were nano-sized particles with smaller particles coating on the inner core and achieved a size of 189.5 nm. HA/GE-DTX/FMN-NPs showed a cellular uptake efficiency of 59.6%, and a more efficient inhibition effect on PC3 cells compared with single ligand-modified NPs and free drugs. HA/GE-DTX/FMN-NPs showed significantly higher tumor inhibition efficiency than their single drug-loaded counterparts and free drugs.
Conclusion: HA/GE-DTX/FMN-NPs have a synergistic anti-tumor effect and also could the reduce unexpected side effects during the cancer therapy. It could be used as a promising anti-PCa system.
© 2022 Dong et al.

Entities:  

Keywords:  binary nanoparticles; docetaxel; epidermal growth factor receptor; formononetin; hyaluronic acid; prostate cancer

Mesh:

Substances:

Year:  2022        PMID: 35983428      PMCID: PMC9380734          DOI: 10.2147/DDDT.S366622

Source DB:  PubMed          Journal:  Drug Des Devel Ther        ISSN: 1177-8881            Impact factor:   4.319


  47 in total

1.  Studies on bioadhesive PLGA nanoparticles: A promising gene delivery system for efficient gene therapy to lung cancer.

Authors:  Weiwei Zou; Chunxi Liu; Zhijin Chen; Na Zhang
Journal:  Int J Pharm       Date:  2008-11-27       Impact factor: 5.875

2.  RGD peptide targeted lipid-coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma.

Authors:  Can Wang; Liang Su; Chengsheng Wu; Jianlin Wu; Chengbao Zhu; Guangying Yuan
Journal:  Drug Dev Ind Pharm       Date:  2016-05-20       Impact factor: 3.225

3.  Formononetin induces the mitochondrial apoptosis pathway in prostate cancer cells via downregulation of the IGF-1/IGF-1R signaling pathway.

Authors:  Wen-Jun Huang; Ling-Yun Bi; Zhen-Zhao Li; Xing Zhang; Yu Ye
Journal:  Pharm Biol       Date:  2013-12-20       Impact factor: 3.503

4.  Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.

Authors:  Yuan Hong; Shaomin Che; Beina Hui; Yunyi Yang; Xiaoli Wang; Xiaozhi Zhang; Yongqian Qiang; Hailin Ma
Journal:  Biomed Pharmacother       Date:  2019-02-21       Impact factor: 6.529

5.  Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer.

Authors:  Wei Fu; Zhiming Hong; Xujun You; Jing Din; Baishu Chen; Beibei Zhao; Gengyan Yuan; Qixin Li
Journal:  Biomed Pharmacother       Date:  2019-09-03       Impact factor: 6.529

6.  Quantitative determination of formononetin and its metabolite in rat plasma after intravenous bolus administration by HPLC coupled with tandem mass spectrometry.

Authors:  Sheelendra Pratap Singh; Dinesh K Yadav; Preeti Rawat; Rakesh Maurya; Girish Kumar Jain
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-12-16       Impact factor: 3.205

7.  Formononetin inhibits colon carcinoma cell growth and invasion by microRNA‑149‑mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways.

Authors:  Ai-Lei Wang; Yong Li; Qun Zhao; Li-Qiao Fan
Journal:  Mol Med Rep       Date:  2018-04-05       Impact factor: 2.952

8.  Combination Therapy of Lung Cancer Using Layer-by-Layer Cisplatin Prodrug and Curcumin Co-Encapsulated Nanomedicine.

Authors:  Yuan Hong; Shaomin Che; Beina Hui; Xiaoli Wang; Xiaozhi Zhang; Hailin Ma
Journal:  Drug Des Devel Ther       Date:  2020-06-09       Impact factor: 4.162

9.  Synergistic combination therapy of lung cancer using lipid-layered cisplatin and oridonin co-encapsulated nanoparticles.

Authors:  Xinglong Fan; Tian Wang; Zhongyi Ji; Qingpeng Li; Hongyu Shen; Jun Wang
Journal:  Biomed Pharmacother       Date:  2021-06-17       Impact factor: 6.529

Review 10.  Focus on Formononetin: Anticancer Potential and Molecular Targets.

Authors:  Samantha Kah Ling Ong; Muthu K Shanmugam; Lu Fan; Sarah E Fraser; Frank Arfuso; Kwang Seok Ahn; Gautam Sethi; Anupam Bishayee
Journal:  Cancers (Basel)       Date:  2019-05-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.